Short answer
SOLENO THERAPEUTICS INC (SLNO) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $66M with net income of $26M.
Q3 2025 key financials · XBRL
- Revenue
- $66M
- +102.2% QoQ
- Net income
- $26M
- +134.0% YoY · +652.5% QoQ
- Operating margin
- 33.5%
- EPS (diluted)
- $0.55
- +128.6% YoY · +1200.0% QoQ
Source: XBRL data from the SOLENO THERAPEUTICS INC (SLNO) Q3 2025 10-Q on SEC EDGAR. USD.
SOLENO THERAPEUTICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: FDA approval of VYKAT XR on March 26, 2025 triggered commercialization challenges and operating expense increases
- Materially updated risk: Debt summary updated with $50M outstanding, potential additional $100M availability, floating interest at SOFR +5.50%
- Regulatory risk: Post-marketing requirements and Orange Book patent challenges risk impacting VYKAT XR commercial exclusivity
- Market risk: Uncertainty in adoption of VYKAT XR due to rare PWS prevalence estimates and third-party payer coverage unpredictability
- Financial risk: Cash $246.7M, marketable securities $309.4M at Sept 30, 2025; need for possible equity or debt financing with dilution or restrictive covenants
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SOLENO THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.